Oregon to Receive $65.6M Under Purdue Pharma Opioid Settlement

An update in the ongoing opioid litigation involving Purdue Pharma shows that the state of Oregon is set to receive $65.6 million as part of a wider $7.4 billion settlement linked to the opioid crisis. 

The settlement, which includes 55 attorneys general representing states and U.S. territories, became effective on April 30. Initial payments include more than $1.5 billion from the Sackler family and $900 million from Purdue. Further payments are scheduled for 2027, 2028 and 2029. 

Oregon’s allocation will be distributed over 15 years across nine payment dates, with more than $14 million expected from the first instalment. According to the Oregon Department of Justice, 55% of the funds will go to cities and counties for opioid crisis abatement, while 45% will be directed to a state board responsible for prevention, treatment and recovery programmes. 

The settlement follows a 2016 investigation into Purdue and the Sackler family’s role in the opioid epidemic. Oregon Attorney General Dan Rayfield stated that the agreement is intended to return funds to communities most affected. 

Purdue Pharma filed for bankruptcy in 2019, and a previous settlement structure was overturned by the US Supreme Court in 2024. Under the current arrangement, Purdue’s manufacturing operations are being transferred to Knoa Pharma LLC, which will operate under separate oversight.